July 1, 2016 / 1:22 PM / a year ago

BRIEF-Aeterna Zentaris, Orient Europharma sign license agreement for Zoptrex

July 1 (Reuters) - Aeterna Zentaris Inc

* Aeterna Zentaris and Orient Europharma Co Ltd sign exclusive license agreement for Zoptrex in Taiwan and Southeast Asia

* Co will be entitled to receive non-refundable upfront payment for license to Cyntec of co’s intellectual property related to Zoptrex

* Company expects to complete Phase 3 clinical trial in Q3 of 2016 for Zoptrex

* Cyntec agreed to make additional payments to co upon achieving certain pre-established regulatory and commercial milestones

* Company will receive royalties on future net sales of Zoptrex in Taiwan, 9 countries in Southeast Asia Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below